| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Integrative Physiology |
From the Department of Molecular Cardiology, Internal Medicine III, J. W. Goethe University, Frankfurt, Germany (J.S.B., M.I., M.K., C.U., A.M.Z., S.D.); and the European Molecular Biology Laboratory (EMBL), Mouse Biology Unit, Rome, Italy (N.R.).
Correspondence to Stefanie Dimmeler, PhD, Department of Molecular Cardiology, Internal Medicine III, University of Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany. E-mail dimmeler{at}em.uni-frankfurt.de
Bone marrow mononuclear cells (BM-MNCs) have successfully been used as a therapy for the improvement of left ventricular (LV) function after myocardial infarction (MI). It has been suggested that paracrine factors from BM-MNCs may be a key mechanism mediating cardiac protection. We previously performed microarray analysis and found that the pleiotropic cytokine interleukin (IL)-10 was highly upregulated in human progenitor cells in comparison with adult endothelial cells and CD14+ cells. Moreover, BM-MNCs secrete significant amounts of IL-10, and IL-10 could be detected from progenitor cells transplanted in infarcted mouse hearts. Specifically, intramyocardial injection of wild-type BM-MNCs led to a significant decrease in LV end-diastolic pressure (LVEDP) and LV end-systolic volume (LVESV) compared to hearts injected with either diluent or IL-10 knock-out BM-MNCs. Furthermore, intramyocardial injection of wild-type BM-MNCs led to a significant increase in stroke volume (SV) and rate of the development of pressure over time (+dP/dt) compared to hearts injected with either diluent or IL-10 knock-out BM-MNCs. The IL-10–dependent improvement provided by transplanted cells was not caused by reduced infarct size, neutrophil infiltration, or capillary density, but rather was associated with decreased T lymphocyte accumulation, reactive hypertrophy, and myocardial collagen deposition. These results suggest that BM-MNCs mediate cardiac protection after myocardial infarction and this is, at least in part, dependent on IL-10.
Key Words: acute myocardial infarction remodeling growth factors/cytokines cell therapy
Related Article:
Circ. Res. 2008 103: 125-127.
This article has been cited by other articles:
![]() |
F. H. Seeger, T. Rasper, M. Koyanagi, H. Fox, A. M. Zeiher, and S. Dimmeler CXCR4 Expression Determines Functional Activity of Bone Marrow-Derived Mononuclear Cells for Therapeutic Neovascularization in Acute Ischemia Arterioscler Thromb Vasc Biol, November 1, 2009; 29(11): 1802 - 1809. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Gersh, R. D. Simari, A. Behfar, C. M. Terzic, and A. Terzic Cardiac Cell Repair Therapy: A Clinical Perspective Mayo Clin. Proc., October 1, 2009; 84(10): 876 - 892. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. D. Zhao, H. Ohkawara, J. Rehman, K. K. Wary, S. M. Vogel, R. D. Minshall, Y.-Y. Zhao, and A. B. Malik Bone Marrow Progenitor Cells Induce Endothelial Adherens Junction Integrity by Sphingosine-1-Phosphate-Mediated Rac1 and Cdc42 Signaling Circ. Res., September 25, 2009; 105(7): 696 - 704. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Penn Importance of the SDF-1:CXCR4 Axis in Myocardial Repair Circ. Res., May 22, 2009; 104(10): 1133 - 1135. [Full Text] [PDF] |
||||
![]() |
P. Krishnamurthy, J. Rajasingh, E. Lambers, G. Qin, D. W. Losordo, and R. Kishore IL-10 Inhibits Inflammation and Attenuates Left Ventricular Remodeling After Myocardial Infarction via Activation of STAT3 and Suppression of HuR Circ. Res., January 30, 2009; 104(2): e9 - e18. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. H. Bishopric Mesenchymal Stem Cell-Derived IL-10 and Recovery From Infarction: A Third Pitch for the Chord Circ. Res., July 18, 2008; 103(2): 125 - 127. [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |